A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma Meeting Abstract
| Authors: | McKean, M.; Luke, J.; Lakhani, N.; Bashir, B.; Aggen, D.; Tan, A.; Kacena, K.; Wang, L.; Timothy, M.; Santillana, S. |
| Abstract Title: | A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma |
| Meeting Title: | 36th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2021) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 9 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Nov 10-14 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-11-01 |
| Start Page: | A425 |
| Language: | English |
| ACCESSION: | WOS:000774877500380 |
| DOI: | 10.1136/jitc-2021-SITC2021.392 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 392 -- Meeting was also presented virtually -- Source: Wos |
